Hinova Pharmaceuticals

Executive Summary

Hinova Pharmaceuticals is a clinical-stage biopharmaceutical company based in Chengdu, China, focused on developing innovative small-molecule therapies for metabolic diseases, particularly diabetes and its complications. Founded in 2013, the company is advancing a pipeline of novel candidates targeting key pathways such as GLP-1 and SGLT2, aiming to offer next-generation treatments with improved efficacy and safety profiles. With a strong focus on the large and growing metabolic disorder market in China and globally, Hinova has positioned itself to address significant unmet needs in diabetes care. The company is currently in Phase 2 clinical development for its lead candidate, leveraging its expertise in medicinal chemistry and translational medicine.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 data readout for lead GLP-1 candidate65% success
• Q3 2026Strategic partnership or out-licensing deal for SGLT2 program50% success
• Q4 2026Series C or later-stage financing round70% success